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Spectrum of renal involvement in familial Mediterranean fever. Kid-
ney biopsies were performed on fifteen patients with a long-standing
history of familial Mediterranean fever (FMF) and evidence of renal
involvement. On light microscopy, seven patients were found to have
amyloidosis, six mesangial proliferative glomerulonephritis (M5PGN)
and two patients rapid progressive glomerulonephritis (RPGN). Immu-
nofluorescent studies of the six biopsies with MsPGN were positive for
mesangial IgA deposits (IgA nephropathy) in three patients and 1gM
mesangial deposits in three (1gM nephropathy). We conclude that in
patients with FMF and renal involvement, non-amyloid renal lesions
(IgA nephropathy, 1gM nephropathy and RPGN) should be considered
in the differential diagnosis in addition to amyloidosis.
Familial Mediterranean Fever (FMF) is an autosomal reces-
sive disorder affecting most commonly Sephardic Jews [1, 2],
Armenians [31, Arabs [4], and a few other ethnic groups living
in the Mediterranean Basin [5, 6]. Two phenotypes of this
disease have been recognized and both comprise attacks and
amyloidosis. The most common recognized form is character-
ized by brief episodic febrile attacks of peritonitis, pleuritis and
synovitis, beginning in childhood or adolescence. Such attacks
are accompanied by a striking elevation of acute phase reac-
tants, including serum amyloid A protein, and finally may be
complicated by amyloidosis [7]. The second phenotype is
characterized by development of amyloidosis first, which is of
the amyloid A protein, and is manifested clinically by nephrop-
athy that passes through different stages of renal involvement,
that is, proteinuria, nephrotic syndrome, uremic stage, to the
death of the patient from renal failure [1, 8]. FMF is inherited as
an autosomal recessive trait. Consanguinity occurs in up to 20%
of the general population affected, and males are more fre-
quently affected than females. Although it is well recognized
that an ethnic variation in the incidence of amyloidosis in FMF
does occur, it is notorious that early death from amyloid is
commonly seen in the Middle Eastern population as a result of
renal involvement [9]. In the last two years, we have described
several renal entities which have been encountered in patients
with FMF in addition to amyloid [10—12]. In this study, we
describe our experience and observation concerning the spec-
trum of renal involvement in patients with FMF.
Methods
Fifteen patients with FMF were referred to the Nephrology
Service at Jordan University Hospital, Amman, for evaluation
and assessment of the degree of renal involvement. Table 1
shows the demographic and clinical data about such individu-
als, and Table 2 shows the different parameters of renal
involvement and results of renal biopsies. Markers for systemic
diseases were excluded in all patients, for example, ASO titer,
rheumatoid factor, HBsAg, ANA, anti-DNA complements,
cryoglobulins, and all were negative. Percutaneous kidney
biopsies were performed on all, utilizing fluoroscopy guidance
in 12, and ultrasonographic guidance in three patients. Light
microscopic examination was performed on all specimens and
immunofluorescent staining in 13. All specimens were stained
with Congo red stain and examined by polarized microscopy
searching for amyloid deposits, as indicated by the presence of
apple green birifringence. Results of kidney biopsies were as
follows (Table 2).
Amyloid deposits were detected in seven biopsies only, and
the remaining eight negative biopsies showed mesangial prolif-
erative glomerulonephritis (MsPGN) in six and rapidly progres-
sive glomerulonephritis (RPGN) in two. Electron microscopic
examination was done on two biopsies from patients with
MsPGN and no amyloid fibrils were detected.
Results
Treatment and outcome
Supportive management, such as salt and water restriction,
occasional use of diuretics and coichicine, was performed to
slow the progression of renal functional impairment. Both
groups with the IgA and 1gM deposits demonstrated some
improvement in kidney function and in the degree of protein
excretion. Patients with RPGN were treated with colchicine,
pulse steroid therapy, plasma exchange and hemodialysis. One
patient improved and he is now off dialysis. The second patient
continued to require hemodialysis until he received a transplan-
tation. In two patients with amyloidosis, kidney function dete-
riorated to the point of requiring hemodialysis support, while in
the remaining five patients, kidney function stabilized.
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A 16-year-old Palestinian male was diagnosed to have FMF
nearly six years earlier following recurrent attacks of severe
abdominal pains and fever once every one to two weeks, each
attack lasting for two to three days. Both the frequency and
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Table 1. Demographic and clinical data on 15 patients with familial Mediterranean fever
Duration
Case
Age
yrs Sex Familiality
of FMF
yrs
Age of onset
renal disease Fever Peritonitis Pleuritis Arthritis
Epididmo Skin
orchitis lesion
1 20 F + 12 16 + + — + — —
2 16 M + 6 16 + + — + + +
3 17 M + 5 17 + + — + — —
4 20 F — 10 20 + + + + — —
5 12 M + 3 12 + + — + — —
6 15 M + 5 15 + + + + + —
7 25 M + 8 25 + + + + — —
8 30 F — 9 NA + + + — — —
9 14 M + 6 14 + + + + + —
10 35 M + 10 30 + + — — — —
11 38 F + 10 36 + + + + — —
12 40 F — 15 NA + + — — — —
13 33 M — 12 30 + + + — — —
14 30 F + 12 5 + + — — — —
15 26 M + 9 NA + + + + — —
Table 2. Results of renal biopsies
Case
Age!
sex
Age of onset
renal disease
Serum
creatinine
mg/dl
Proteinuria Light
g/24 hr microscopy
Immunoflourescence
Colchicine
C3 treatmentIgG IgA 1gM
1 20/F 16 5.2 4.5 Amyloidosis — — 1+ 1+
2 16/M 16 1.1 2.3 MsPGN (AN) — 3+ — 1+ 6 years
3 l7/M 17 0.8 1.6 MsPt3N (AN) — 3+ — 2+ Intermittent
4 20/F 20 0.8 2.3 MsPGN (AN) — 3+ 1+ — Few months
5 12/M 12 9.5 4.5 RPGN (AN) — — 2+ 3+ Intermittent
6 15/M 15 10.8 8.4 RPGN (AN) 2+ — 1+ 3+ 2—3 years
intermittent
7 25/M 25 0.9 1.3 MsPGN (AN) — — 3+ 2+ 2 years
8 30/F NA 2.5 3,8 Amyloidosis NA NA NA NA Intermittent
9 14/M 14 1.1 0.9 MsPGN (AN) — — 2+ 1+ Intermittent
10 35/M 30 3.8 3.2 Amyloidosis NA NA NA NA No
11 38/F 36 0.9 1.5 MsPGN (AN) — — 2+ — Intermittent
12 40/F NA 1.8 1.0 Amyloidosis 1+ — — 1+ 5 years
intermittent
13 33/M 30 1.5 1.8 Amyloidosis NA NA NA NA 3 years
intermittent
14 30/F 5 4.5 12 Amyloidosis 2+ — — 1+ Intermittent
15 28/M NA 0.7 0.8 Amyloidosis — — — — Intermittent
Abbreviations are: MsPGN, mesangial proliferative glomerulonephritis; RPGN, rapidly progressive glomerulonephritis; NA, not available; AN,
amyloid negative. Immunoflourescence range: mild 1+; moderate 2+; strong 3+.
severity of the attacks diminished once colchicine was started.
Two days prior to admission he developed fever and abdominal
pains, large joint arthralgias together with scrotal pain, swelling
and redness of the skin above the right ankle. There were no
chest pains or any urinary symptoms. Family history of similar
illness was present, both an older sister and a younger brother
suffer from the same illness and are being treated with colchi-
cine.
Upon admission, clinical examination revealed temperature
of 38.5°C, pulse 110/minute and blood pressure of 110/75 mm
Hg. The patient looked sick and mildly dehydrated. Both chest
and cardiac examinations were normal. Abdominal tenderness
and guarding were present, liver span was 10 cm, the spleen
was not palpable and bowel sounds were absent. The scrotum
was swollen, red, tender and both the right testicle and the
epididymis were also swollen and tender (epididymo-orchitis).
Both elbows, wrists and knees were swollen and tender with
limitation ofjoint movement. The skin above the right malleolus
was red, indurated and tender (erysipelas-like lesion). There
was no peripheral edema. The clinical impression was an acute
attack of FMF with epididymo-orchitis.
Laboratory data revealed the following: hemoglobin 13.3
gldl, hematocrit 38.7%, white blood cells 14,200/cm3 with 75%
polymorphonuclear cells, a platelet count of 220,000 and ESR
64 mm/hr. Serum urea nitrogen was 18 mg/dl, serum creatinine
1.1 mg/dl, serum sodium 134 mEq/liter, serum potassium 4.2
mEq/liter, serum calcium 9.8 mg/dl, total protein 6.8 g/dl and
serum albumin 3.3 g/dl. Liver enzymes were normal and serum
fibrinogen level was 650 ms/dl. Urinalysis showed 2+ protein, 2
to 4 white blood cells and 8 to 12 red blood cells per high power
field; few granular but no red cell casts were seen. Twenty-four
hour urine collection revealed 2.3 g protein. Both urine and
throat cultures were negative. Results of serological tests for
HBsAg, rheumatoid factor, antinuclear antibodies, cryoglobu-
lins, antistreptolysin titer and serum complements all were
normal. Serum immune globulin revealed an elevated IgA level
of 425 mgldl (normal: 150 to 300 mg/UI) and a normal IgG and
1gM level.
On light microscopic examination of the kidney biopsy spec-
imen, 16 glomeruli were seen. All showed diffuse mesangeal
proliferative glomerulonephritis with occasional polymorpho-
nuclear cells. There was no sclerosis or crescent formation (Fig.
1). Congo red stain was negative for amyloidosis. Immuno-
fluorescent staining was strongly positive for IgA(+ ++) and
C3(+) in a granular pattern in the mesangium (Fig. 2).
Colchicine 0.6 mg orally was given every hour for a total of
five doses, and resulted in marked improvement of the abdom-
inal pains, scrotal swelling, skin lesion and joint swelling. After
that he was maintained on colchicine 0.6 mg twice daily; when
he was seen in the clinic two, four and six months later he was
asymptomatic. Urinalysis showed 1 + protein, 1 to 2 red cells
per high power field and 0.6 gram protein excretion per 24
hours. Serum creatinine was 0.8 mgldl and the serum albumin
4.1 g/liter.
Comment. This case represents non-amyloid glomerular dis-
ease (IgA nephropathy) in a patient with FMF.
Discussion
Familial Mediterranean Fever (FMF) is an autosomal reces-
sive disorder which affects mainly Sephardic Jews, Armenians
and Arabs and it is characterized by recurrent episodes of
polyserositis and fever [2]. The pathogenesis of this disorder is
not known, but since its initial description in 1945 [13], several
authors have suggested hypersensitivity and genetic or autoim-
mune mechanisms [14, 15]. FMF is potentially a fatal illness
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Fig. 1. Light micrograph demonstrating
d/fuse mesangial proliferation. HE X 360.
Fig. 2. Fluorescence micrograph
demonstrating the mesangial pattern of
localization of labelled antibody of IgA.
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Table 3. Familial Mediterranean fever and renal amyloidosis
Author [Ref] Year Country Ethnic group
No. of patients
with FMF
No. of patients
(%) with
amyloid
Ehrenfeld et al [17] 1961 Israel Sephardic Jews 55 4 (7.2%)
Sohar et al [2) 1967 Israel Sephardic Jews 470 114 (26.5%)
Khachadarian et at [20] 1974 Lebanon Armenians 120 9 (7.5%)
Schwabe and Peters [3] 1974 USA Armenians 100 0
Reimann et at [21] 1954 Lebanon Arabs 23 0
Hitar et al [23] 1974 Lebanon Arabs 52 4 (8%)
Bakeer and Murtada [24] 1975 Iraq Arabs 50 2 (4%)
Barakat et at [4] 1986 Kuwait Arabs 175 3 (1.7%)
Hamad et al [25] 1971 Egypt Arabs 11 0 (0%)
Wahib et at [26] 1989 Saudi Arabia Arabs 20 0 (0%)
Ozer et at [28] 1971 Turkey Turks 20 12 (60%)
Said et al [current studyl 1991 Jordan Arabs IS 7 (46.5%)
40% of patients were Arabs
owing to the high incidence of renal amyloidosis that compli-
cates this disorder [2, 16]. In fact, the development of amyloid-
osis has been recognized as an ominous prognostic feature of
this disease.
The frequency of this complication varies among the different
ethnic groups and countries (Table 3). In the Sephardic Jews of
Israel, [2, 17, 18] the incidence of amyloidosis is higher (7.2%
up to 26.5%) than that in the Ashkenazi Jews of the United
States [19], where it is close to zero. Similarly, among the
Armenians the incidence of amyloidosis complicating FMF
varies dramatically and depends upon where they reside and if
amyloidosis was seriously considered in their diagnoses. In a
series of 120 Armenian patients with FMF residing in Lebanon,
Khachadurian and Armenian [20] reported an incidence of
7.5%, while in the one hundred Armenians residing in the
United States reported by Schwabe and Peters [3], no single
case of amyloidosis was reported.
Among Arab patients with FMF, the frequency of amyloid-
osis is also quite variable, ranging from 0 to 25%. The reason for
this latitude seems to depend on how completely such patients
were tested and if amyloidosis was seriously considered when
the diagnosis was decided. Reimann et al [21] studied 23 Arab
patients with FMF at the American University Hospital in
Beirut and found no single case of amyloidosis among them. In
1958 Tuqan [22] was the first to document the presence of
amyloidosis during autopsy; it was found in two young Arab
boys who died with renal failure complicating FMF. Later,
Bitar et at [23] reported four cases (8% of amyloidosis) among a
group of 52 patients with FMF (40% of them were Arabs). In
1975, Bakeer and Murtada [24] reported two cases (4% of renal
amyloidosis) among 50 patients suffering from FMF in Iraq.
Similarly, Barkat et al [4] reported only 1.7% of amyloidosis
among 175 patients with FMF who were residing in Kuwait.
Surprisingly, no single case of amyloidosis has been reported
among Arab patients with FMF residing in Egypt [25] or Saudi
Arabia [26]. In contrast, Amr and Hamzeh [27] reported 20
cases of renal amyloidosis from Jordan in 1985, of which five
patients (25%) suffered from FMF.
This in fact represents the highest figure reported from the
Arab world prior to our current series (7 out of 15 patients with
an incidence of 46.5%). This high incidence of amyloidosis in
our FMF patients who developed renal disease is not a true
reflection of the incidence of amyloidosis in FMF patients in the
Arab world. Similarly, high figures of renal amyloidosis have
been reported from other countries in the Middle East. Sohar et
al [2], who are from Israel, reported a frequency of 26.5%
among 470 Sephardic Jews with FMF. Similarly, Ozer, Kapla-
man and Zileli [28] from Turkey, reported a 60% incidence of
amyloidosis among the 20 patients with FMF in his series.
In addition to amyloidosis, other renal lesions have been
described in patients with FMF. In 1955, Shwayri and Tutunji
[29] described a case of recurrent abdominal and thoracic pains
(FMF) with synchronous gross hematuria, but no tissue diag-
nosis was available. In 1970, Eliakim et a! [181 analyzed renal
manifestations in 106 patients with FMF and found that 66%
had no renal involvement, 12.3% had amyloidosis and 21.7%
had renal lesions other than amyloid. Patients in this last
category clinically presented with transient or persistent hema-
turia and albuminuria, particularly during attacks, and a variety
of glomerulonephritis, including acute post-streptococcal gb-
merulonephritis and hypersensitivity angiitis. Histologically a
good number of kidney biopsies showed mesangial proliferative
glomerubonephritis, but no immunofluorescent studies were
available. In 1982, Flatau, Kohn and Schiller [301 reported 10
episodes of Henoch-Schonlein purpura (HSP) in eight patients
with FMF, and kidney biopsies were performed in two patients
which showed focal mesangial proliferative glomerulonephritis
with granular mesangial C3 deposits in one patient only, but
there were no IgA, IgG and 1gM deposits.
During the last two years, we were successful in describing a
variety of non-amyloid renal lesions in patients with FMF. In
1988, we reported the presence of intense mesangial IgA
deposits in a granular pattern in two patients with a long history
of FMF [10]. Both patients were found to have proteinuria,
microscopic hematuria and elevated serum IgA levels during
the acute attacks. Treatment with cotchicine resulted in both
subsidence of the acute attacks and a decrease in the degree of
proteinuria. A third case has been added recently, and it is
presented here in our series in detail, as an illustrative example.
In 1989, we reported the presence of rapid progressive
glomerulonephritis (RPGN) type 2 without amyloidosis in two
patients with FMF. Both patients presented with gross hema-
tuna and oliguria, and they were found to be in renal failure;
kidney biopsy showed RPGN in both [11]. In 1990 we also
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reported the presence of 1gM nephropathy in three patients with
FMF in the absence of amyloidosis [12]. Again, these three
patients were found to have both microscopic hematuria and
proteinuria during the acute episodes of FMF. Excellent recov-
ery and response to colchicine was obtained, both clinically and
in the form of normalization of urinary function.
The presence of the immunoglobulin IgA and 1gM mesangial
deposits in patients with FMF may represent an immunoreac-
tant mechanism or simple entrapment of these substances as the
result of the mesangial dysfunction in clearing and processing
immunologically-irrelevant macro-molecular aggregates. The
frequent association of mesangial C3 and as well as mesangial
proliferation has been invoked in support of an immuno-
pathological role in these cases. Similarly, recent evidence
suggests that an immunological mechanism may play a major
role in the pathogenesis of FMF [31]. The findings of immune
complexes in 50% of patients with FMF [32], complement
consumption during attacks [33], the increase in the level of
urinary fibrogen degradation products and the return of these
tests to normal at the end of acute attacks [31], are good
supportive evidence that an immunological process may under-
lie FMF. Thus, the finding of both mesangial 1gM and IgA
deposits in patients with FMF may represent an immune
reactant mechanism rather than chance alone. In addition, the
occurrence of type 2 RPGN in patients with FMF is not
surprising, because this represents immune complex-mediated
disease. In view of the clear association and the clinical
similarities between HSP and FMF [30], the occurrence of IgA
nephropathy in both FMF [10] and HSP [34], and the fact that
both IgA nephropathy and HSP are associated with type 2
RPGN [35], it is not surprising that this disorder has been
encountered among patients with FMF. In spite of the fact that
we report eight cases of non-amyloid glomerular disease among
15 patients with FMF, there are no good epidemiological
studies showing that non-amyloid glomerular disease is more
frequent in patients with FMF than in the general population;
however, amyloid renal disease is definitely more common in
FMF patients than in the general population [16].
Finally, some of our patients were taking colchicine intermit-
tently when they developed the non-amyloid glomerular dis-
ease, but not amyloidosis. It is possible that the use of this drug,
even intermittently, played a major role in preventing the
development of amyloidosis in this group of patients, as has
been suggested recently by Zemer et al [36]. Of equal impor-
tance is the improvement of renal findings in the same group of
patients when colchicine was given in large doses to suppress
the acute attack of FMF [37], and then maintained on a regular
basis afterwards. It is possible that such a high dose may also
suppress the acute inflammatory changes affecting the kidneys.
However, this is speculation and further studies are needed.
In conclusion, renal involvement in FMF includes both
amyloid and non-amyloid glomerular diseases, and colchicine
treatment is quite effective in both treating the acute attack and
the prevention of amyloidosis in FMF.
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